
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Principal Investigator (?)
Study Number
F18074
Summary
This study will evaluate the long-term safety and tolerability of VX-659 in triple
combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis
(CF) who are homozygous or heterozygous for the F508del mutation.
Phase (?)
Phase III
Sponsor (?)
Vertex Pharmaceuticals, Inc
Contact
Available at the following location(s)
Lebanon,Manchester